Quintrio
Home

Stock overview

HUTCHMED (China) Limited American Depositary Shares

HCM

HUTCHMED (China) Ltd is a biopharmaceutical company engaged in the discovery, development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. The company has a portfolio of several cancer drug candidates currently in clinical studies world-wide and an extensive commercial infrastructure in its home market, China. The company operates in two reportable segments: Oncology/Immunology and Other Ventures.

Last trade $14.42
Day change -$0.31 (-2.10%)
Day range $14.31 – $14.76
Volume 28,222
Market cap $2.56B

Open XNAS

Fundamentals

Key company ratios and reported financial statements.

Source: Massive.com

Key ratios

No ratio data was found for HCM.

Financial statements

Income and cash flow amounts are for the period; balance sheets are point-in-time snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are displayed when available.

No quarterly income statement data was found for HCM.

Recent news

Company coverage with links to the original publishers.

Publication times in UTC
GlobeNewswire Inc.

HUTCHMED Announces Sovleplenib Granted US FDA Orphan Drug Designation for Autoimmune Hemolytic Anemia

HUTCHMED announced that the US FDA has granted Orphan Drug Designation to sovleplenib for treating autoimmune hemolytic anemia (AIHA), marking the second orphan designation for the drug following its recent designation for primary immune thrombocytopenia (ITP). The designation provides 7 years of US market exclusivity upon approval, along with other development incentives. NDAs for sovleplenib are currently under regulatory review in China for primary ITP and warm AIHA.

GlobeNewswire Inc.

HUTCHMED Announces Sovleplenib Granted US FDA Orphan Drug Designation for Primary Immune Thrombocytopenia

HUTCHMED announced that the US FDA has granted Orphan Drug Designation to sovleplenib for treating primary immune thrombocytopenia (ITP), a rare autoimmune disorder. The designation provides 7 years of US market exclusivity upon approval, along with other development incentives. Sovleplenib is a novel, selective oral spleen tyrosine kinase inhibitor currently under regulatory review in China for ITP and warm antibody autoimmune hemolytic anemia.

GlobeNewswire Inc.

Save the Date: HUTCHMED to Host Expert Insights Event on Recent Savolitinib Clinical Data in Non-Small Cell Lung Cancer

HUTCHMED announced an expert webcast on November 5, 2026, to discuss Phase III clinical data for savolitinib in MET-driven NSCLC. The SANOVO study showed savolitinib plus TAGRISSO® reduced disease progression/death risk by 44% overall and 55% in high MET overexpression patients. The SAFFRON global Phase III trial demonstrated a 45% reduction in progression risk and 32% reduction in death risk in EGFR-mutated lung cancer after TAGRISSO® progression.

GlobeNewswire Inc.

HUTCHMED Announces Closing of KRAS-EGFR-Antibody Conjugate Therapy License to GSK Outside China

HUTCHMED has completed an exclusive development and license agreement with GSK subsidiary, granting GSK worldwide rights (excluding Greater China and Taiwan) to develop and commercialize HMPL-A830, a first-in-class KRAS-EGFR antibody-targeted therapy conjugate. HUTCHMED will receive $110 million upfront and up to $1.185 billion in milestone payments, plus tiered royalties. HUTCHMED remains responsible for global Phase I development.

GlobeNewswire Inc.

HUTCHMED Announces Submission of US NDA for ORPATHYS® plus TAGRISSO® in MET-Driven EGFR-Mutated Lung Cancer

HUTCHMED announced that AstraZeneca has submitted a New Drug Application (NDA) to the FDA for ORPATHYS® (savolitinib) combined with TAGRISSO® (osimertinib) to treat patients with MET-driven EGFR-mutated non-small cell lung cancer who progressed on EGFR-TKI therapy. The submission is supported by the SAFFRON Phase III trial, which demonstrated statistically significant improvements in progression-free survival and overall survival compared to platinum-based chemotherapy.

Dividends

Declared distributions and recorded event dates. Forecasts are not shown.

Updated daily

No declared upcoming dividend found.

No prior dividend records found.

Stock splits

Historical share-structure events and their execution dates.

Updated daily
Execution dateSplit ratioEvent type
Apr 20, 20091-for-50reverse split